The presentation revealed the details of the company’s broadly cross-reactive antigens that are designed to protect people from pandemic and seasonal influenza. The vaccine is in development.
"As the world's leader in the production of influenza vaccines, Sanofi Pasteur's ambition is to drive innovation and to shape the future by exploring several of the leading influenza vaccine strategies," Sanofi Pasteur President and CEO Olivier Charmeil said.
This is the 16th year that the World Vaccine Congress has been held in Europe. It is designed to gather vaccine leaders so they can share the developments happening in their field.
"We are actively exploring the development of a more-broadly protective influenza vaccine that will be designed to prevent the seasonal mismatches that can occur and that are not addressed using the current technology," Harry Kleanthous, Sanofi Pasteur's associate vice president for research, said. "They are complementary but can be considered 'tailored' antigens in that they are designed to re-focus the immune response to key protective epitopes on the hemagglutinin, which is the active component of our currently licensed influenza vaccines. These antigens are still a key player in any flu vaccine, since antibodies directed against them are responsible for preventing the Flu virus from binding to and infecting the cell. Creating new antigens is a central theme in our strategy."
Sanofi Pasteur, the vaccines division of Sanofi, is a global company that provides more than 1 billion doses of vaccine each year, making it possible to immunize more than 500 million people across the globe.